Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology


Novel therapies for thyroid cancer

ea0035s22.2 | Novel therapies for thyroid cancer | ECE2014

Limits of targeted therapies and future developments

Leboulleux Sophie

Targeted therapies have been used for about 10 years in patients with radioactive iodine refractory differentiated thyroid cancer (DTC) or metastatic medullary thyroid cancer (MTC). Decrease in tumor volume, improvement of symptoms, increase in progression free survivals have been observed with different drugs. So far, because of trial design and because of the long survival of patients with metastatic DTC or MTC, the benefit of these drugs on overall survival has not been dem...

ea0035s22.3 | Novel therapies for thyroid cancer | ECE2014

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Fagin J

Oncogenic activation of MAPK in thyroid cells leads to loss of expression of genes required for thyroid hormone biosynthesis, including the sodium iodide transporter (NIS) and thyroid peroxidase (TPO). Tumors with BRAF mutation have lower expression of NIS, explaining in part why BRAF-mutant PTCs are often resistant to RAI therapy. We developed mouse models of thyroid cancer driven by BRAFV600E, and these tumors also lose the ability to concentrate radioiodine, whic...